This recall was issued due to superpotency or amounts of desmopressin higher than specified, which may represent a potential safety risk.

What do you need to do?

• Do not stop taking your medication without speaking with your doctor. The U.S. Food and Drug Administration (FDA) recommends that patients continue taking their medication, as the risk of harm to a patient's health may be higher if the treatment is stopped immediately without any alternative treatment.
• Please call your doctor right away to obtain a new prescription for another appropriate medication. Your doctor will be able to prescribe another medication for you so you can continue treating your condition without interruption. 

To get more information or to report any adverse events or quality problems experienced with the use of this product, you can contact CSL Behring directly, or you can report to the FDA's MedWatch Program.

• Manufacturer Information:

CSL Behring:
Phone: 800.504.5434
Email: MedinfoNA@cslbehring.com

• To report an adverse event to the FDA Med Watch Program:

Online: https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program/reporting-serious-problems-fda

Regular Mail or Fax: Download form https://www.fda.gov/safety/medical-product-safety-information/forms-reporting-fda mail or submit by fax to 800.FDA.0178

Affected NDCs:

Lot	Exp Date	NDC #
Stimate® Nasal Spray 1.5 mg/mL, 2.5 mL
N14134C	07/2020	0053-6871-00
N15378G	09/2020	0053-6871-00
N17445N	12/2020	0053-6871-00
P11326AA	02/2021	0053-6871-00
P11326C	02/2021	0053-6871-00
P13209L	04/2021	0053-6871-00
P13212H	06/2021	0053-6871-00
P13755A	06/2021	0053-6871-00
P13756P	08/2021	0053-6871-00
R11845A	04/2022	0053-6871-00
R13271A	04/2022	0053-6871-00
R13648A	06/2022	0053-6871-00
R14101A	07/2022	0053-6871-00
R14667A	08/2022	0053-6871-00
R15953C	09/2022	0053-6871-00